Welcome

Celebrating Over 75 Years Of Service

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Dedicated to enhancing knowledge and skill in the care of the allergic patient."

ADVOCACY UPDATES

Your AAOA at the AMA

I want to urge you to consider membership in the AMA because your membership in…

read more

Fall Advocacy Update: USP 797, E/M Documentation and Payment

Revisions to USP Chapter 797 Open for Comment Since the United States Pharmacopeia (USP) released…

read more

Brief Update on the Final CY 2019 Physician Fee Schedule

On November 1, the Centers for Medicare and Medicaid Services released the final Physician Fee…

read more

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

12/01/2018: Research Grant Cycle
Learn more

04/01/2019: 2019 Fellow Exam Application Deadline
Learn more

06/01/2019: Research Grant Cycle

06/7/19: Membership Application Deadline to be eligible for AAOA Member rate for the 2019 Basic Course

07/31/19: Membership Application Deadline to be voted in at the 2019 Annual Meeting and to be eligible for AAOA Member Rate (FREE) for the 2019 Annual Meeting
Learn more

EDUCATION

Codes/Guidelines

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

IFAR

IFAR Impact Factor: 2.135

aaoaf-ifar

Now Available

Changes in Managing Practices

Mission

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2019 Interactive Allergy & Rhinology Course
February 8-10, 2019 | Dallas, TX
Learn More and Register

2019 Basic Course in Allergy & Immunology
June 27-29 | Minneapolis, MN
Save the Date

2019 AAOA Annual Meeting
September 13-15 | New Orleans, LA
Save the Date

2019 Advanced Course in Allergy & Immunology
December 12-14 | Austin, TX
Save the Date

AAOA Clinical Insights
Learn More and Register

PATIENT CORNER

OTC Allergy Medications

There seem to be more and more medications available for allergy treatment that  you can now purchase over the counter.
The FDA is allowing previously prescription only drugs to be made available directly to the consumer without a prescription — adding more to the over-the-counter options in the healthcare aisles.

Read More

News and Updates

From the AAOA President, Matthew Ryan, MD

...the AAOA continues to be the organization that Otolaryngologists look to for up-to-date education and information on the…

read more

FDA Approves First Generic Version of EpiPen

The Food and Drug Administration approves the first generic version of EpiPen and EpiPen Jr.…

read more

Social and Networking Events at the 2018 AAOA Annual Meeting

This year’s Annual Meeting assures to be not only educational, interactive, and practice-centered, but also…

read more

Menu
AAOA Logo

About Us

AAOA SCOPE OF KNOWLEDGE: ALLERGY AND ASTHMA

You can also download The Scope of Knowledge PDF.

I Epidemiology

A. Prevalence

  • i Regional
  • ii Change Over Time

B. Populations at risk

  • i Genetic associations
  • ii Environmental associations

C. Socioeconomic impact of disease

  • i Direct cost
  • ii Indirect costs
  • iii Quality of life

II Science of the Sites of Allergic Inflammation

A. Anatomy, Histology, physiology, pathophysiology of:

  • i Nose and paranasal sinuses
  • ii Pharynx
  • iii Ear/Eustachian Tubes
  • iv Larynx/Trachea
  • v Lungs
  • vi Eye
  • vii Skin
  • viii Gastrointestinal tract

B. Basic physiology, pathophysiology, and principles of:

  • i Mucociliary function
  • ii Smell and taste
  • iii Auditory/vestibular function
  • iv Voice
  • v Respiratory function
  • vi Deglutition
  • vii Ocular protection mechanisms
    • 1 Naso–lacrimal function
    • 2 Conjunctival function
  • viii GI function

III Basic Science

A. Basic components, concepts and applications pertinent to Allergy:

  • i Immunology
    • 1. Function
      • a. General aspects
        • i Recognition
        • ii Surveillance
        • iii Amplification
        • iv Memory
      • b. Triggers of the immune response
        • i Allergens, haptens, epitopes, parasites, macromolecules
      • c. Categories of response
        • i Innate
        • ii Adaptive
    • 2. Components
      • a. Inflammatory cells
        • i Macrophages (APC)
        • ii Lymphoid
          • 1 T–cells
          • 2 B–Cells
          • 3 Null cells
        • iii Granulocytes
          • 1 Mast Cells/basophils
          • 2 Eosinophils
          • 3 Neutrophils
          • 4 Platelets
      • b. Immunoglobulins
        • i G
        • ii A
        • iii M
        • iv D
        • v E
      • c. Inflammatory mediators
        • i Cytokines
        • ii Chemokines
        • iii Vasoactive amines
        • iv Leukotrienes
        • v Prostaglandins
        • vi Complement
  • ii Endocrinology
  • iii Neurology
  • iv Molecular cell biology
  • v Genetics

B. Physiology and pathophysiology

  • i Immunology
    • 1. Cellular communication
      • a. Direct contact
        • i Antigen specific
      • b. Cytokine/Chemokine mediated
        • i Non-antigen specific
    • 2. Inflammatory pathways
      • a. Cellular
        • i Microphage
        • ii Granulocyte
          • 1 Mast Cell/Basophils
          • 2 Eosinophil
      • b Non-cellular
        • i Complement
        • ii Arachadonic Acid cascade
        • iii Other
    • 3. Immune sensitization
      • a Memory
    • 4. Hypersensitivity (Gel and Coombs)
      • a I
      • b II
      • c III
      • d IV
      • e V
      • f VI
  • ii Allergic response (Type I)
    • 1 Allergy sensitization
      • a Antigen processing
      • b T-cell
      • c B-cell
      • d IgE
      • e Mast cell
    • 2 Subsequent exposure—trigger
      • a Mast Cell
        • i Antigen crosslinking
        • ii Degranulation
          • 1 Preformed mediators
          • 2 Newly synthesized mediators
          • 3 Cytokines
      • b Early phase response
      • c Late phase response
        • i Cellular Components
      • d Priming
  • iii Microbiology
    • 1 Parasitology
    • 2 Bacteriology
    • 3 Virology
    • 4 Mycology
  • iv Endocrinology
  • v Neurology
  • vi Molecular cell biology
  • vii Genetics
  • viii Nutrition

IV Diseases, Disorders, and Conditions

A. Differential diagnosis of inflammatory disease:

  • i Nose/paranasal sinus
  • ii Otologic
  • iii Laryngopharyngeal
  • iv Tracheobronchial
  • v Thoracic/Pulmonary
  • vi Gastrointestinal
  • vii Ocular
  • viii Cutaneous

B. Immunologic disorders

  • i. Allergic diseases
    • 1. Allergic Rhinitis
    • 2. Allergic conjunctivitis
    • 3. Otologic disease
      • a. Otitis media
      • b. Meniere’s
      • c. Otitis externa
      • d. Eustachian tube dysfunction
    • 4. Asthma
    • 5 Dermatitis
      • a. Eczema
      • b. Contact
      • c. Urticaria/Angioedema
    • 6. Allergic laryngitis
    • 7. Gastrointestinal
      • a. Eosinophilic esophagitis
  • ii Co-morbid conditions impacted by allergy
    • 1. Rhinosinusitiss
    • 2. Otitis media
    • 3. Eustachian tube dysfunction
    • 4. Disordered sleep
    • 5. Laryngeal/pharyngeal/esophageal disorders
      • a. GERD
    • 6. Asthma
  • iii Immunodeficiency
  • iv Autoimmune diseases

V Diagnostics and Assessment Procedures

A. History

  • i Symptoms
    • 1. Onset, duration, severity
    • 2. Triggers
    • 3. Exacerbating or ameliorating factors
  • ii Exposures
    • 1. Temporal relationships
      • a. Intermittent
      • b. Persistent
    • 2. Identifiable antigen
      • a. Aeroantigens (Inhalants)
      • b. Ingestants
      • c. Contactants
      • d. Injectants
  • iii Co-morbid conditions
    • 1. Rhinosinusitiss
    • 2. Otitis media
    • 3. Eustachian tube dysfunction
    • 4. Disordered sleep
    • 5. Laryngeal/pharyngeal/esophageal disorders
      • a. GERD
    • 6. Asthma
    • 7. Ocular
  • iv Family/childhood history

B. Physical examination

  • i Face
  • ii Ears
  • iii Nose/Paranasal sinues
  • iv Oro/Nasopharynx
  • v Laryngotracheal
  • vi Pulmonary
  • vii Skin

C. Adjunctive testing: Indications, limitations, and normal and pathologic findings:

  • i Ears
    • 1. Audiovestibular testing
  • ii Nose
    • 1. Acoustic rhinometry/rhinomanometry
    • 2. Nasal cytology/biopsy
    • 3. Nasal/paranasal sinus culture
    • 4. Nasal endoscopy
    • 5. Olfactory testing
    • 6. Radiologic testing
  • iii Larynx
    • 1. Laryngoscopy
  • iv Pulmonary
    • 1. Pulmonary function testing
    • 2. Radiologic testing
  • v Sleep
    • 1. Polysomnography

D. Allergy testing:

    • i Antigen selection
      • 1. Antigen characteristics
        • a. Aeroallergen physical characteristics
        • b. Biologic activity/potency
        • c. Antigen cross reactivity
        • d. Antigen extraction/standardization
      • 2. Aeroallergen distribution
        • a. Principles of distribution
        • b. Local and Regional differences
      • ii Aeroallergen tests
        • 1. Expanded specific allergen testing
          • a. In vivo
            • i Principles of in vivo testing
              • 1. Pathophysiology of the skin whealing response
                • a. Immediate response
                • b. Delayed response
              • 2. Factors that affect the skin whealing response
            • ii Specific methodologies
              • 1. Percutaneous (Prick) testing
                • a. Single percutaneous (prick) testing
                • b. Multi percutaneous (prick) testing
              • 2. Intradermal testing
                • a. Single intradermal testing
                • b. Intradermal dilutional testing
              • 3. Blended techniques of in vivo testing
              • 4. Scratch testing (mentioned only for historical purposes)
              • 5. Provocation
          • b. In vitro
            • i Principles of in vitro testing
            • ii Methodologies
    • 2. Principles of the allergen screen
      • iii Ingestants (Food Allergy)
        • 1. History
          • a. Food diary
          • b. Anaphylaxis
        • 2. Testing
      • iv Injectants
      • v Contactants
        • 1. Contact tests (patch)

E. Immunologic Evaluation (including rheumatologic)

      • i Humoral
      • ii Cellular

VI Allergy Treatment

A. Environmental control
B. Pharmacotherapy/pharmacology

      • i Antihistamines
      • ii Decongestants
      • iii Mast cell stabilizers
      • iv Mucolytics
      • v Leukotriene modifiers
      • vi Corticosteroids

C. Dietary control

D. Immunotherapy

    • i. Desensitization
      • 1. Route of delivery
        • a. Subcutaneous
        • b. Mucosal (e.g., sublingual)
      • 2. Mechanism of action/li>
      • 3. Indications/contraindications
      • 4. Antigen dosing
        • a. Starting dose
        • b. Escalation
        • c. Maintenance
        • d Withdrawal
      • 5. Mixing of treatment vial
      • 6. Duration of therapy
      • 7. Outcomes of immunotherapy
    • ii Monoclonal antibody

VII Allergy Emergencies


A. Epidemiology

  • i Risk factors
  • ii Recognition
  • iii Differential diagnosis

B. Management

  • i High-risk population recognition
  • ii Preparation
  • iii Prevention
  • iii Intervention
scope

Register For Live Classes

2017 Advanced Course in Allergy & Immunology
December 6-9 | Vail, CO.
Learn more and Register

2018 Interactive Allergy & Rhinology Course
February 22-24 | Dallas, TX
Save the Date

2018 Basic Course in Allergy & Immunology
July 5-7 | Hollywood, FL
Save the Date

2018 AAOA Annual Meeting
September 14-16 | Philadelphia, PA
Save the Date

Clinical Insights With Wiley
Start Learning Now

Spotlight/News

Recent Blog Articles

From the AAOA President, Matthew Ryan, MD

...the AAOA continues to be the organization that Otolaryngologists look to…

read more

FDA Approves First Generic Version of EpiPen

The Food and Drug Administration approves the first generic…

read more

Congress Makes Changes to MACRA

The second year of the Quality Payment Program (QPP)…

read more

* Adapted from Marple, BF, et al. “American Academy of Otolaryngic Allergy CME Report: Allergy, Scope of Knowledge.” Otolaryngology—Head and Neck Surgery, 136(1): 8-10, 2007 Jan